Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease

Table 1 Demographic and clinical data of patients participating in the study

Therapy	IBD patients with loss of response, side effects, hypersensitivity(n = 6)	Control IBD patients(n = 1)
Mean age at diagnosis, yr	34.9 (17-67)	36.4 (17-66)
Mean disease duration at biological therapy, yr	7.1 (1-20)	7.7 (1-21)
CD/UC	19/17	17/14
Male/female	14/22	14/17
Previous biological therapy	22	15
Concomitant steroid therapy	5	3
Concomitant thiopurine therapy	18	16
Previous surgery	16	7
Active disease	25	0

CD: Crohn’s disease; UC: Ulcerative colitis; IBD: Inflammatory bowel disease.